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Abstract 
Background: An analysis of the US National Cardiovascular Data Registry has revealed that 
only 38% of patients referred for coronary angiography after non-invasive coronary testing 
have relevant coronary obstruction (CO) (≥70%) of one or more coronary arteries.  
Methods: A single-center trial was undertaken in 165 consecutive, symptomatic patients 
with either known or suspected coronary disease and/or valve disease(VHD) who agreed to 
undergo cardiac catheterization and coronary angiography if stress myocardial perfusion 
imaging was abnormal. A total of 116 patients with abnormal SPECT MPI tests, persistent 
chest pain, or significant VHD underwent final analysis. An MCG coronary obstruction (CO) 
score of ≥ 4.0 was considered indicative of relevant CO (≥70%) in one or more coronary 
arteries. Angiographic results were finalized by consensus of two angiographers.  
Results: CO (≥70%) was present in 53 of 116 patients (46%). The MCG CO score was 
significantly higher for patients with relevant CO (5.4 ± 1.9 vs. 2.5 ± 1.9). The MCG correctly 
classified 103 of the 116 patients (89%) enrolled in the study as either having or not having CO 
(≥70%) (sensitivity- 91%; specificity- 87%; NPV- 92%; PPV- 86%). SPECT MPI was abnormal in 
99 of the 116 (85%) patients undergoing catheterization, but correctly classified only 54 of the 
116 patients (47%) entered in the study as either having or not having relevant CO (sensi-
tivity-85%; specificity–14%; NPV – 53%; PPV- 45%).  
Conclusions: The MCG was shown in this paired-comparison trial with SPECT MPI to safely 
and accurately identify patients with relevant CO (≥70%) prior to catheterization. 
Key words: Coronary Angiography, Coronary Artery Stenosis, MultiFunction CardioGram 
Introduction 
Coronary  artery  disease  is  the  single  leading 
cause of death in the US and the developed world [1]. 
However, recent data from an expanded analysis of 
the National Cardiovascular Data Registry in the US 
has  revealed  that  only  38%  of  patients  referred  for 
coronary angiography, as a result of accepted meth-
ods  of  non–invasive  coronary  testing  actually  have 
relevant CO (≥70%) of one or more coronary arteries 
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[2],  strongly  suggesting  that  current  non-invasive 
testing  does  not  accurately  identify  patients  who 
should undergo coronary angiography. 
The  Multifunction  Cardiogram™  (MCG)  has 
been  studied  as  an  innovative  computational  elec-
tro-physiologic  signal  analysis  tool  for  the 
non-invasive  diagnosis  of  relevant  CO/ischemia 
(≥70%)  [6-10].  In  three  previous  double-blind,  con-
trolled, clinical trials of patients scheduled to undergo 
elective coronary angiography [6-9] MCG accurately 
identified 88% of the patients finally found to either 
have or not have relevant CO (≥70%). Limitations of 
these  studies  included  the  lack  of  a  standardized 
non-invasive  diagnostic  testing  algorithm  prior  to 
angiography making it difficult to compare the pre-
dictive value of MCG to that of SPECT MPI or other 
non-invasive  diagnostic  testing  modalities,  and  that 
the  indications  for  angiography  varied  among  pa-
tients. The purpose of this prospective, single-center, 
blinded  trial  was  to  address  these  limitations  and 
further  evaluate  the  accuracy  of  MCG  testing  by  a 
paired-comparison  to  stress  SPECT  MPI  in  patients 
referred for coronary angiography because of an ab-
normal SPECT MPI test. 
Materials and Methods 
165  consecutive  symptomatic  patients  with 
known or suspected coronary disease and/or valvu-
lar heart disease (VHD) who agreed to undergo MCG 
Testing,  Stress  SPECT  MPI  with  sestamibi,  resting 
TTE, and a coronary angiogram (CA) if stress SPECT 
MPI results showed evidence of ischemia, and/or if 
significant VHD was present, and/or if recurrent or 
persistent  chest  pain  was  present  despite 
non-ischemic  stress  SPECT  MPI  were  enrolled.  The 
trial  protocol  was  approved  by  the  Valley  Hospital 
Institutional Review Board. Stress MPI studies were 
all performed using standard SPECT techniques and 
VHD  was  defined  using  ASE  guideline-based  rec-
ommendations  for  severity  assessment  with  TTE. 
Based on data from previously conducted trials [6-10], 
an MCG CO score of ≥ 4.0 was considered abnormal 
and indicative of the presence of relevant CO (≥70%) 
in one or more coronary arteries or bypass grafts. 49 
patients with either normal or equivocal stress MPI 
results,  and  insignificant  VHD,  and  no  persistent 
chest pain were not recommended for CA, and, thus 
were excluded from analysis in the trial. These 49 pa-
tients have continued to undergo clinical surveillance 
since  enrolled.  116  patients  who  underwent  MCG 
testing and showed either abnormal stress MPI (stress 
defects with partial or complete reperfusion), and/or 
significant VHD on TTE , and/or recurrent chest pain 
despite a non-ischemic stress MPI (normal perfusion 
images  or  fixed  defects  with  no  reperfusion  [ische-
mia]) were referred for CA, and included in the trial 
analysis. All myocardial perfusion data were acquired 
using  ECG-gating  and  attenuation  correction,  and 
were analyzed visually and semi-quantitatively using 
Cedars Sinai Polar Map Analysis software with inclu-
sion of perfusion, wall motion, and wall thickening 
data. Standard nuclear stress test interpretation crite-
ria were used to define the presence/absence of ab-
normal myocardial perfusion. MCG final reports and 
stress  MPI  interpretations  were  completed  prior  to 
catheterization  in  all  cases.  Patients  enrolled  in  the 
trial  may  or  may  not  have  had  prior  angiography 
and/or coronary intervention. 
When  the  angiographic  data  was  analyzed  in 
patients with/without previous bypass grafting, the 
presence of ischemia was defined as CO ≥ 70% in na-
tive coronary vessels or bypass grafts affecting one or 
more of the major coronary distributions (LAD, LCX, 
and RCA) or ≥ 50% stenosis of the left main coronary 
artery.  Angiographic  results  in  all  patients  were 
evaluated quantitatively for relevant stenosis (≥ 70%) 
by consensus of two angiographers at the time of the 
catheterization. The second angiographer in all cases 
was an interventional cardiologist who was blinded to 
the MCG and SPECT MPI results. The personnel in-
volved in obtaining the SPECT MPI data were blinded 
to  the  MCG,  TTE,  and  cardiac  catheterization  data, 
and  the  personnel  acquiring  the  MCG  data  were 
blinded to the SPECT MPI, the TTE, and catheteriza-
tion data. Patients were blinded to their MCG score 
but not their TTE, MPI, or catheterization data.  
The patients in this study were 35–84 years old, 
had known or suspected CAD with current coronary 
symptoms, had an intermediate pre-test risk of CAD 
by risk factor analysis, did not have an acute coronary 
syndrome, did not have a revascularization procedure 
or myocardial infarction within three months of entry, 
had no overlap with any previous MCG study or with 
the  normalized  MCG  clinico-pathologic  database  of 
patients (see below). The MCG database and analysis 
software was not modified during the study period. 
Patient  characteristics  (name,  date-of-birth,  sex, 
height,  weight),  along  with  a  minimum  of  three  82 
second samples of resting two-lead (lead II and V5) 
ECG  data,  regardless  of  the  ECG  rhythm  or  mor-
phology, were recorded on each patient entered and 
sent via the internet to the network center for objec-
tive analysis and reporting. 
MCG Device and Database 
The MCG device used in all patients in the study, 
is  manufactured  in  the  US  by  Premier  Heart,  LLC, 
Port  Washington,  NY,  and  records  a  simultaneous Int. J. Med. Sci. 2011, 8 
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2-lead resting ECG signal from leads II and V5 for 82 
seconds,  using  proprietary  hardware  and  software. 
The  digitized  MCG  ECG  data  along  with  patient’s 
name, date-of-birth, sex, height, and weight are en-
crypted (256-bit) by the device at the study location 
and securely transmitted over the Internet to a central 
server located in New York, NY for final analysis and 
reporting of the MCG CO score (0-20).  
At the central server location in New York, a se-
ries  of  Discrete  Fourier  Transformations  (DFT)  and 
post-DFT signal averaging are performed on the data 
from the patient’s two resting ECG leads followed by 
signal  averaging.  The  final  averaged  digital  data 
segment is then subjected to six mathematical trans-
formations (auto and cross power spectra, coherence, 
phase angle shift, impulse response, cross correlation, 
transfer function, and an amplitude histogram) which 
generate  a  large  inventory  of  empirically  derived 
normalized  mathematical  indexes.  The  resulting 
mathematically  integrated  patterns  of  the  abnormal 
indexes are then compared for degree of abnormality 
to the index patterns in the reference database to reach 
a  final  diagnostic  output.  The  diagnostic  output  is 
represented as a combination  of the overall disease 
severity  score  from  0  to  20  and  an  indicator  of  the 
presence of local or global ischemia, which together 
indicate the level of coronary obstruction/myocardial 
ischemia that is present in the study patient. 
The database against which the incoming MCG 
data  are  compared  originated  from  data  gathering 
trials conducted from 1978 to 2000 in more than 30 
institutions in Europe, Asia, and North America on 
~100,000 individuals of varying ages and degrees of 
coronary  disease  including  a  normal  population  at 
each age [11]. The MCG database consists of ~10,000 
validated normal patients and ~30,000 validated pa-
tients  with  varying  degrees  of  severity  of  coronary 
disease.  Ages  range  from  14  to  100  with  an  equal 
number  of  patients  and  49%  females  in  every  age 
range  in  the  database.  All  MCG  data  and  analyses 
included in the database were performed using the 
same standardized and calibrated analog signal col-
lection  and  processing  equipment  as  in  the  current 
trial and were analyzed using the same software and 
hardware located at the central server location in New 
York. All MCG analyses in this database have been 
validated against the final medical and angiographic 
diagnoses,  confirmed  by  two  US  independent  aca-
demic  angiographers  having  access  to  all  the  diag-
nostic  tests  including  angiography  results,  lab,  and 
cardiac  enzyme  test  results.  The  MCG’s  current  di-
agnostic capability for identification of local or global 
ischemia and the disease severity score used in this 
clinical study is based on this large proprietary data-
base  of  validated  MCG  analyses  accumulated  since 
1990. See Appendix in (7) for further details. 
Statistical Methods 
Descriptive statistics were calculated for all var-
iables  including  confidence  intervals.  Differences 
between paired or two unpaired mean values were 
analyzed with the t-test, and degrees of freedom were 
adjusted according to a variance estimate if the F-test 
could  not  show  equality  of  variances.  Differences 
between more than two mean values were analyzed 
with the Scheffé test where homogeneity of variances 
was assessed with the Levene statistic. For two-way 
and multi-way tables, Fisher’s exact test was used to 
calculate significance levels. 
Odds ratios including 95% confidence intervals 
were calculated for all variables. Positive and negative 
predictive values (PPV, NPV) for the assessment of 
CO were calculated with adjustment to prevalence of 
stenosis [12]. To assess the performance of the predic-
tion of stenosis independent of the prevalence of ste-
nosis, the positive and negative likelihood ratios (LR) 
were calculated [13]. A value of p <0.05 was consid-
ered statistically significant. All analyses were done 
with SPSS for Windows Version 15 (SPSS Inc., Chi-
cago, IL, USA). 
Results 
Final analysis was performed on 116 patients. No 
patients  were  excluded  from  the  study  because  of 
poor quality MCG tracings or uninterpretable SPECT 
images. The 49 patients excluded from analysis sig-
nificantly  differed  from  the  included  patients  with 
respect to age (61.7 +/- 13.1 vs. 67.3 +/- 11.3. years; p 
<  0.05)  and  sex  (44.9%  excluded  females  vs.  29.3% 
included females; p < 0.05). Only eight percent (8%) of 
patients (4/49) excluded had an abnormal MCG CO 
score ≥ 4 with evidence of moderate/severe local is-
chemia. These patients are being followed closely for 
major adverse coronary events.  
Twenty of the 116 patients (17%) included in the 
study had previous coronary artery bypass grafting 
12 or more weeks before inclusion in the study. Pa-
tients  with  previous  coronary  bypass  grafting  were 
significantly older (p <0.05) and more frequently male  
Relevant CO was diagnosed by angiography in 
53 of 116 patients (46%). There were no significant age 
differences between patients with and without angi-
ographically proven relevant CO (p = 0.4). There were 
however significant gender differences with regard to 
the finding of relevant CO at angiography (29% fe-
male vs 52% male) (p <.02).  
Patients without a significant CO had an MCG 
CO score < 4.0 (mean 2.5 ± 0.25 SEM) more frequently Int. J. Med. Sci. 2011, 8 
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than those with a relevant CO (CO score ≥ 4.0) (mean 
5.4 ± 0.26 SEM) by a wide margin (p <0.001) (Figure 
1). The results indicate that MCG in this study had a 
sensitivity of 91% (0.79 – 0.97 CI) and a specificity of 
87% (0.76 – 0.94 CI) for the prediction of CO. The pos-
itive predictive value (PPV) was 0.86 (0.74 – 0.94 CI), 
and  the  negative  predictive  value  (NPV)  was  0.92 
(0.81 – 0.97 CI). (Table 1). SPECT Nuclear sensitivity 
in the study was 85% (0.72 – 0.93 CI), specificity was 
14% (0.07 – 0.25 CI), PPV was 46% (0.35 – 0.56 CI), and 
NPV was 53% (0.28 – 0.77 CI) overall.  
 
Figure 1. MCG CO Score vs. coronary stenosis 
(all patients). Boxplots of MCG CO scores in all pa-
tients with and without relevant coronary stenosis. The 
boundaries of the box are Tukey’s hinges. The median is 
identified by the line inside the box. The length of the box 
is the interquartile range (IQR) computed from Tukey’s 
hinges. Values more than three IQR’s from the end of a 
box are labeled as extreme, denoted with an asterisk (*). 
Values more than 1.5 IQR’s but less than 3 IQR’s from 
the end of the box are labeled as outliers (•). Whiskers 
show high/low values. Outliers and Extremes were in-
cluded in the overall statistical analysis because the as-
sumptions  about  the  distribution  of  the  data  (normal 
distribution) were not violated. 
 
 
 
Table 1. Composite Data 
    Results  Disease  Test Results     a piori             
  n  TP  TN FP  FN Dis+ Dis- Test+  Test- Correct #  Correct % Risk % Sensitivity Specificity PPV  NPV LR+  LR- 
MCG vs. Cath                                     
Total  116 48  55  8  5  53  63  56  60  103  89%  46%  0.906  0.873  0.857 0.917 7.132 0.108 
female  34  10  20  4  0  10  24  14  20  30  88%  29%  1.000  0.833  0.714 1.000 6.000 0.000 
male  82  38  35  4  5  43  39  42  40  73  89%  52%  0.884  0.897  0.905 0.875 8.616 0.130 
< 65 yoa  52  14  31  5  2  16  36  19  33  45  87%  31%  0.875  0.861  0.737 0.939 6.300 0.145 
65+ yoa  64  34  24  3  3  37  27  37  27  58  91%  58%  0.919  0.889  0.919 0.889 8.270 0.091 
no CABG  96  37  48  8  3  40  56  45  51  85  89%  42%  0.925  0.857  0.822 0.941 6.475 0.088 
CABG  20  11  7  0  2  13  7  11  9  18  90%  65%  0.846  1.000  1.000 0.778 NaN 0.154 
no diabetes  99  38  49  8  4  42  57  46  53  87  88%  42%  0.905  0.860  0.826 0.925 6.446 0.111 
diabetes  17  10  6  0  1  11  6  10  7  16  94%  65%  0.909  1.000  1.000 0.857 NaN 0.091 
no arterial hyperten-
sion 
29  12  12  3  2  14  15  15  14  24  83%  48%  0.857  0.800  0.800 0.857 4.286 0.179 
arterial hypertension  87  36  43  5  3  39  48  41  46  79  91%  45%  0.923  0.896  0.878 0.935 8.862 0.086 
no anemia  104 43  50  6  5  48  56  49  55  93  89%  46%  0.896  0.893  0.878 0.909 8.361 0.117 
anemia  12  5  5  2  0  5  7  7  5  10  83%  42%  1.000  0.714  0.714 1.000 3.500 0.000 
no LV hypertrophy  69  27  34  6  2  29  40  33  36  61  88%  42%  0.931  0.850  0.818 0.944 6.207 0.081 
LV hypertrophy  47  21  21  2  3  24  23  23  24  42  89%  51%  0.875  0.913  0.913 0.875 10.06 0.137 
                                     
Nuclear vs. Cath                                     
Total  116 45  9  54  8  53  63  99  17  54  47%  46%  0.849  0.143  0.455 0.529 0.991 1.057 
female  34  8  2  22  2  10  24  30  4  10  29%  29%  0.800  0.083  0.267 0.500 0.873 2.400 
male  82  37  7  32  6  43  39  69  13  44  54%  52%  0.860  0.179  0.536 0.538 1.049 0.777 
< 65 yoa  52  15  3  33  1  16  36  48  4  18  35%  31%  0.938  0.083  0.313 0.750 1.023 0.750 
65+ yoa  64  30  6  21  7  37  27  51  13  36  56%  58%  0.811  0.222  0.588 0.462 1.042 0.851 
 
 Int. J. Med. Sci. 2011, 8 
 
 
http://www.medsci.org 
721 
Figure 1, a boxplot of MCG CO scores versus the 
documented presence or absence of relevant CO by 
coronary angiography, demonstrates the clear sepa-
ration of the mean and median MCG scores in the two 
groups (p < .01) of patients with and without relevant 
CO (≥70%). Figure 2 illustrates a boxplot of MCG CO 
scores from the gender subgroups showing that MCG 
was equally discriminatory between men and women 
at detecting the presence of relevant CO. In Figure 3, 
the MCG data from patients above and below the age 
of 65 in the study, demonstrated the ability of MCG to 
clearly separate those with and without relevant CO 
in the two age groups.  
MCG Sensitivity averaged between 85% and 92% 
with only two exceptions (females and patients with 
anemia where sensitivity was 100%). MCG specificity 
also varied between subgroups from 83% to 91% with 
few exceptions such as the anemia subgroup (71%), 
patients with normal blood pressure (80%), patients 
with diabetes (100%), and patients with prior CABG 
(100%).  In  these  subgroups,  the  number  of  patients 
was too low to achieve meaningful statistics.  
However,  MCG  accurately  classified  30/34 
(88%) women as either having or not having relevant 
CO  while  SPECT  MPI  accurately  classified  10/34 
(29%) women as either having or not having relevant 
CO. For the female subgroup, MCG sensitivity was 
100%,  specificity  83%,  and  NPV  was  100%,  while 
SPECT sensitivity was 80%, specificity was 8%, and 
NPV  was  50%.  These  differences  were  statistically 
significant with a p < 0.01. 
For patients 65 years old or older the MCG sen-
sitivity  was  92%,  the  specificity  was  89%,  and  the 
positive and negative predictive values were 92% and 
89% respectively. The SPECT MPI sensitivity in pa-
tients over the age of 65 was 81% and the specificity 
was 22% with a positive and negative predictive value 
of 59% and 46% respectively. (Table 1.) 
In paired-comparison, Table 2 shows that MCG 
and SPECT MPI testing were false indicators of rele-
vant CO 6.9% of the time and were both correct indi-
cators  of  the  presence  of  relevant  CO  40.5%  of  the 
time.  However,  MCG  was  the  correct  indicator  CO 
and  SPECT  MPI  was  the  incorrect  indicator  of  CO 
47.4% of the time, while MCG was the incorrect indi-
cator of CO and SPECT MPI was the correct indicator 
of CO only 5.2% of the time.  
 
 
 
Figure 2. MCG CO Score vs. coronary stenosis vs. sex. Boxplots of MCG CO scores in all patients with and without 
relevant coronary stenosis. (See Figure 1 Legend for further explanation of boxplots.) 
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Figure 3. MCG CO Score vs. coronary stenosis vs. age groups. Boxplots of MCG CO scores in all patients 
with/without relevant coronary obstruction. (See Figure 1 Legend for further explanation of boxplots.) 
 
 
Table 2. Correct Detection of CAD Defined by Angiographic Results: MCG Compared to SPECT Nuclear Testing (ab-
solute numbers of patients and percentages). 
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Discussion 
The  overall  diagnostic  sensitivity  of  91%  and 
specificity of 85% of the MCG test documented in a 
meta-analysis [10] of the published MCG clinical trials 
had confirmed the diagnostic utility of this device to 
predict the presence of relevant CO (≥70%) in a pop-
ulation with a demonstrated intermediate pre-test risk 
of disease (27.7% to 43.4%). The current trial is a di-
rect, paired-comparison of the accuracy of the MCG 
test and of SPECT MPI in predicting the existence of 
relevant  CO  (as  determined  by  coronary  angi-
ography)  in  consecutive  symptomatic  patients  un-
dergoing  typical  sequential  non-invasive  evaluation 
for  the  presence  of  anatomically  relevant  CO.  The 
study was not designed or powered to show superi-
ority  of  one  modality  over  another  in  the  trial,  but 
simply to assess the accuracy of each modality used in 
the same patient in predicting the presence or absence 
of anatomically relevant CO. 
The study population had an overall CAD pre-
test  probability  of  46%  (Intermediate  Risk  by  Dia-
mond-Forrester criteria [20]). The study only permit-
ted patients with an abnormal SPECT MPI test, sig-
nificant VHD with/without a normal SPECT MPI test, 
or patients with persistent coronary symptoms and a 
normal SPECT MPI test to undergo cardiac catheteri-
zation. While the MCG findings were consistent with 
the prior published data [6-10], SPECT MPI was asso-
ciated with a high number of false positives (46%) that 
led to angiography in 54 patients whose management 
did not change based on the results, therefore, argua-
bly making the angiogram medically unnecessary. 
One limitation of the present study was that the 
anatomic obstructions were not explicitly quantified, 
in all patients, using a suitable scoring system such as 
the BARI (Bypass Angioplasty Revascularization In-
vestigation) system [18] and there was no systematic 
functional  analysis  of  lesion  severity  (induction  of 
ischemia)  using  techniques  of  Fractional  Flow  Re-
serve.  Regardless,  the  assessment  of  the  anatomic 
coronary lesions in the present study was made by 
two experienced US based angiographers who inde-
pendently  visually  evaluated  the  angiograms  and 
agreed on the severity grading of obstructions. As the 
target criterion was an anatomic CO (≥70%), implying 
the need for an interventional treatment strategy, it is 
possible that borderline lesions were classified incor-
rectly as less  severe (<70%). This  may  have further 
artificially reduced the calculated specificity of both 
the MCG and SPECT MPI methods. 
Another  limitation  is  the  single-center  enroll-
ment of patients. Although this may limit the gener-
alizability of the findings, the demographic distribu-
tion of this patient population matches those reported 
in the literature for symptomatic patients undergoing 
evaluation for CAD[2, 14-17, 19]. In addition, 54% of 
all the participants, 71% of women, and 42% of pa-
tients aged ≥ 65 did not have relevant CO on angi-
ography,  with  MCG  CO  scores  ranging  from  com-
pletely normal (0.0-0.5) to less than 4.0. This is similar 
to the findings of other studies, appearing to justify 
the  study  population’s  applicability  to  the  general 
population of coronary disease patients in the US as 
described by Patel [2]. In the Patel study, less than half 
of the patients referred for catheterization due to ab-
normal stress imaging or CT angiographic data, were 
actually  found  to  have  anatomically  severe  CO 
(≥70%).  
Finally,  enrolling  patients  with  valvular  heart 
disease with symptoms suggestive of coronary insuf-
ficiency  could  have  further  reduced  specificity  of 
SPECT MPI due to documented examples of reduced 
coronary flow reserve in these patients. However, of 
the 8 patients with moderate to severe VHD enrolled 
in the study, three patients had abnormal SPECT MPI. 
Only  1  of  these  three  patients  with  an  abnormal 
SPECT MPI had no significant CO (i.e. < 70%), while 2 
with  an  abnormal  SPECT  MPI  had  significant  CO 
(≥70%) on catheterization demonstrating inclusion of 
these patients had little impact on overall study re-
sults. 
In conclusion, the MCG device provides a highly 
sensitive and specific test for the detection of relevant 
CO, in a real world population of patients at low or 
intermediate pre-test risk of CO. The findings of this 
study strongly suggest that these patients will benefit 
from MCG testing when being considered for coro-
nary angiography because an MCG CO score of < 4 
indicates the patient can be safely managed medically 
without the need for invasive evaluation.  
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